Clinical Trials
18 trialsNCT00492050 2026-03-11
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03620903 2025-12-05
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
University of Ulm
Phase 2 Active not recruiting
NCT03697356 2023-10-06
Ballondor
Kosin University Gospel Hospital
Phase 2 Recruiting
NCT01592981 2021-06-18
R2W
University College, London
Phase 2 Completed
NCT01046006 2021-04-30
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
University of Athens
Phase 2 Completed
NCT00422799 2020-10-27
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00980395 2019-12-30
VCR
University of Arizona
Phase 2 Completed
NCT00711828 2019-04-16
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Mayo Clinic
Phase 2 Completed
NCT03335098 2017-11-07
BOMB-THROW
Seoul National University Hospital
Phase 2 Unknown
NCT01536067 2016-06-10
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00250926 2016-04-08
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated
NCT00723658 2015-03-06
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00832234 2015-02-18
BDR-WM
European Myeloma Network B.V.
Phase 2 Completed
NCT00045695 2013-05-17
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00777738 2013-01-18
WM2
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00142129 2011-06-27
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00265928 2008-01-28
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated